Sir, Several studies among patients undergoing cardiac surgery (CS) have reported post-operative pneumonia (POP) as the main infectious complication 1,2 usually involving nosocomial microorganisms. 1 Due to the therapeutic issues raised by Pseudomonas aeruginosa infections, the choice of appropriate initial empirical antibiotic therapy (EAT) is of major importance, but has been minimally addressed in CS patients. We compared the incidence, risk factors, microbiological features, therapeutic management and outcome of POP due to P. aeruginosa with POP due to other organisms in this setting.
This single-centre study performed in a tertiary care hospital from January 2005 to October 2007 prospectively evaluated 2540 patients undergoing CS with cardiopulmonary bypass admitted to a post-operative 15 bed CS intensive care unit (ICU). Cefamandole was used for surgical antibiotic prophylaxis (allergic patients received vancomycin þgentamicin). Diagnosis of POP was based on usual clinical and microbiological criteria, with bronchoalveolar lavage yielding bacteria at a concentration of .10 4 cfu/mL or protected distal bronchial specimen samples yielding .10 3 cfu/mL. Susceptibility testing was performed using the disc diffusion method. Eighty-two (3.2%) patients were diagnosed as having POP a median (interquartile range) of 4 (2) days after surgery, including 47 cases of ventilator-associated pneumonia (VAP) (57%) and 26 cases of POP due to P. aeruginosa (32%). A total of 122 microorganisms were cultured. POP due to P. aeruginosa was more frequently observed as a monomicrobial infection (65% versus 37% in other cases of POP, P ¼0.02). In POP due to P. aeruginosa, most isolates were susceptible to the antibiotic agents, except for one P. aeruginosa strain resistant to piperacillin, three P. aeruginosa strains (12%) resistant to imipenem and three Enterobacteriaceae strains (50%) resistant to amoxicillin/ clavulanate. In the other group, 44% (n¼ 16) of Enterobacteriaceae were susceptible to amoxicillin/clavulanate and 100% were susceptible to broad-spectrum b-lactams and fluoroquinolones. One Acinetobacter strain was resistant to piperacillin/ tazobactam. POP due to P. aeruginosa was evenly distributed over the study period, with no evidence of clustering. Surveillance isolates from the environment showed that all isolates were different.
EAT was more frequently inappropriate in the group with POP due to P. aeruginosa than in the other cases of POP (38% versus 7%, P, 0.001) ( Table 1) . In multivariate analysis, POP due to P. aeruginosa was independently associated with previous antibiotic exposure in the 3 months before surgery [odds ratio (OR) 6.6; 95% confidence interval (CI) 1.8 -25.2; P ¼ 0.005], presence of a nasogastric tube (OR 6.8; 95% CI 1.5 -31.8; P ¼ 0.02), Simplified Acute Physiologic Score (SAPS II) 4 per one point increase (OR 1.1; 95% CI 1.0 -1.2; P ¼ 0.003) and chronic obstructive pulmonary disease (COPD) (OR 6.0; 95% CI 1.5 -23.0; P ¼ 0.01). The model showed good calibration (Hosmer -Lemeshow goodness of fit test: P ¼ 0.61) and discrimination [area under the receiver operating characteristic (ROC) curve: 0.83 (95% CI 0.75 -0.93)].
Twenty-nine patients (35%) died after an interval of 15 (19) days following surgery; 15 (58%) of the 26 cases of POP due to P. aeruginosa versus 14 (25%) deaths among the other 56 patients (P¼ 0.004). Death was reported in 8 (57%) of the 14 patients who received inadequate EAT compared with 21 (31%) deaths among the 68 patients with adequate EAT (P ¼ 0.07).
Publications of POP following CS have usually confined their analysis to patients with VAP. 1, 2 We consider that extending the study population to non-VAP patients provides an interesting perspective, as VAP is not the only clinical presentation of POP, as illustrated by a study in which VAP represented only 36% of all cases of POP.
5
Local guidelines are not used frequently in CS patients. 2 Our local guidelines for EAT of nosocomial pneumonia take into account previous antibiotic therapy and duration of ICU stay, in line with the American Thoracic Surgery (ATS) guidelines. 6 The attending physician should consider patients with POP as potentially harbouring multidrug-resistant (MDR) pathogens, while a low risk of multidrug resistance is only observed in early-onset nosocomial pneumonia ( 4 days). 6 In all instances, a selection between limited-spectrum antibiotic therapy and broadspectrum treatment targeting MDR strains is based on this early/late onset segmentation.
In light of our results, the risk of MDR pathogens in CS patients seems low, but the risk of POP due to P. aeruginosa justifies the use of broad-spectrum agents. The guidelines for initial EAT for CS patients with suspected POP have been modified in our institution. A stratification based on underlying diseases (presence of COPD), previous antibiotic therapy and severity of infection more accurately identifies patients suspected of harbouring P. aeruginosa strains. In these high-risk patients, broad-spectrum antibiotic agents targeting non-fermenting Gram-negative bacilli (piperacillin/tazobactam or imipenem alone or combined with aminoglycosides or ciprofloxacin) are used as EAT. Limited-spectrum antibiotic therapy (amoxicillin/ clavulanic acid or cefotaxime alone or combined with aminoglycosides or ciprofloxacin) is used in the remaining patients. This policy is similar to the ATS statements applied for patients suspected of harbouring multiresistant strains, 6 but previous duration of risk exposure could be of limited value in post-operative patients. The type of antibiotic prophylaxis is another risk factor to consider in the emergence of P. aeruginosa infection, but this issue remains to be assessed.
This single-centre study cannot provide any definitive conclusions for other institutions. As a consequence, our results should be considered cautiously. However, our observations are an incentive to establish recommendations for EAT for POP after CS.
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